ViRelieve is a development-stage biotech company focused on developing novel anti-viral therapeutics to treat respiratory syncytial virus (RSV) and parainfluenza viruses (PIVs) infections using protein-protein interference technology. The company is led by Ivan Ivanov, PhD (President & CEO), Filip Yabukarski, PhD (CSO), Origene Nyanguile, PhD (VP of preclinical development) and Craig Shimasaki, PhD, MBA (Business development director). Our seasoned management team has strong expertise and complementarity in the scientific field, pharmaceutical drug development and experience in the management and development of the biotechnology business.
ViRelieve is exploiting a newly-discovered and proprietary technology platform that blocks the replication of a virus during infection. This technology platform targets and interrupts protein-protein interactions essential for the replication of many related viruses. This technology platform can also be applied against a wide range of human pathogenic viruses, such as rabies, measles, ebola and influenza to name a few. The first commercial product the company is pursuing is a treatment for RSV and PIV infections, as currently there is no adequate therapy.
Mission and vision
The mission of the company is to address the unmet medical need for respiratory anti-viral therapeutics causing morbidity and mortality in the most venerable individuals of our society – the very young and the elderly.